Acelarin

A gemcitabine phosphoramidate prodrug that can overcome the key cancer resistance; NUC-1031 is significantly less dependent on deoxycytidine kinase and on nucleoside transporters, and it is resistant to cytidine deaminase-mediated degradation compared with gemcitabine; inhibits L1210 and BxPC-3 cell proliferation with IC50 of 35 nM and 150 nM, respectively; significantly reduces tumor volumes in vivo in pancreatic cancer xenografts.Pancreatic Cancer Phase 3 Clinical (In Vitro) :Gemcitabine is a nucleoside analogue commonly used in cancer therapy but with limited efficacy due to a high susceptibility to cancer cell resistance. The addition of a phosphoramidate motif to the gemcitabine can protect it against many of the key cancer resistance mechanisms. A series of gemcitabine phosphoramidate prodrugs are synthesized and screened for cytostatic activity in a range of different tumor cell lines. Among the synthesized compounds, NUC-1031 is shown to be potent in vitro. (In Vivo) :The ProTide demonstrates a significant reduction in tumor size against pancreatic xenograft models compared with the gemcitabine treated group, and less adverse effects on body weight, indicating a better safety profile. Data strongly suggests that the ProTides are not reliant on kinases or nucleoside transporters to exert their activity inside tumor cells and remain stable in the presence of deaminases. The ProTide NUC-1031 is currently advancing through phase I/II clinical studies and has already generated strong pharmacokinetic data that confirm significantly higher intracellular levels of gemcitabine triphosphate, together with promising early efficacy signals and a favorable safety profile. The phosphoramidate chemistry is potentially a great source of new and very effective anticancer agents, bringing a considerable array of advanced treatments specifically designed to overcome cancer resistance mechanisms that will benefit a greater proportion of patients.

840506-29-8

NUC-1031 | NUC1031 | NUC 1031 | CPF-31

>98% (HPLC)

DMSO: ≥ 36 mg/mL

C[C@H] (NP (OC1=CC=CC=C1) (OC[C@H]2O[C@@H] (N3C=CC (N) =NC3=O) C (F) (F) [C@H]2O) =O) C (OCC4=CC=CC=C4) =O

C25H27F2N4O8P

580.4744484

Storage temperature: -20°C. Stability: ≥ 2 years

For research use only.